文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

降钙素原或C反应蛋白指导脓毒症重症成人抗菌药物停用的获益与危害:系统评价与网络Meta分析

Benefits and Harms of Procalcitonin- or C-Reactive Protein-Guided Antimicrobial Discontinuation in Critically Ill Adults With Sepsis: A Systematic Review and Network Meta-Analysis.
PubMed 文献 · Crit Care Med · 2024-07-01
一句话结论在脓毒症成人中,降钙素原或C反应蛋白指导的抗菌药物停用策略可能有益且安全,降钙素原指导可缩短抗菌疗程并降低死亡率。

该系统评价与网络Meta分析纳入18项随机对照试验、共5023例重症成人脓毒症患者,比较降钙素原或C反应蛋白指导的抗菌药物停用策略与标准治疗。降钙素原指导缩短抗菌治疗-1.89天(95%CI -2.30至-1.47),C反应蛋白指导缩短-2.56天(95%CI -4.21至-0.91),证据确定性低至中等。降钙素原指导降低死亡率(每1000例减少27例[95%CI -45至-7]),在Sepsis-3中更明显;C反应蛋白指导对死亡率无差异。两种策略均未显著增加复发(证据确定性极低至低)。作者认为在Sepsis-3、抗菌药物使用超过7天时降钙素原指导有用。

要点

  • 降钙素原指导停用抗菌药物缩短疗程-1.89天(95%CI -2.30至-1.47),证据确定性低至中等。
  • C反应蛋白指导停用抗菌药物缩短疗程-2.56天(95%CI -4.21至-0.91),证据确定性低至中等。
  • 降钙素原指导降低死亡率(每1000例减少27例[95%CI -45至-7]),在Sepsis-3中更明显;C反应蛋白指导对死亡率无差异。
  • 降钙素原指导的获益在基线抗菌疗程较短(7-10天)或Sepsis-3亚组中一致,在降钙素原 cutoff「0.5 μg/L且降低80%」时更明显;监测频率低于初始10天的一半时未见获益。
  • 两种策略均未显著增加复发(证据确定性极低至低)。

适用人群与场景

  • 重症监护病房中的成人脓毒症患者(纳入的随机对照试验人群)。

诊断标准与关键阈值

  • 降钙素原指导方案中,降钙素原 cutoff 为「0.5 μg/L且降低80%」时获益更明显。
  • 监测频率低于初始10天的一半时,降钙素原指导未见获益。

处置流程与药物剂量

  • 降钙素原指导的抗菌药物停用策略可缩短抗菌治疗时间(-1.89天[95%CI -2.30至-1.47]),并降低死亡率(每1000例减少27例[95%CI -45至-7]),在Sepsis-3中更明显。
  • C反应蛋白指导的抗菌药物停用策略可缩短抗菌治疗时间(-2.56天[95%CI -4.21至-0.91]),但对死亡率无差异。

研究设计与关键结果

  • 系统评价与网络Meta分析纳入18项随机对照试验、共5023例重症成人脓毒症患者。
  • 降钙素原指导策略缩短抗菌治疗-1.89天(95%CI -2.30至-1.47),C反应蛋白指导策略缩短-2.56天(95%CI -4.21至-0.91),证据确定性低至中等。
  • 降钙素原指导的获益在基线抗菌疗程较短(7-10天)或Sepsis-3亚组中一致,在降钙素原 cutoff「0.5 μg/L且降低80%」时更明显;监测频率低于初始10天的一半时未见获益。
  • 降钙素原指导降低死亡率(每1000例减少27例[95%CI -45至-7]),在Sepsis-3中更明显;C反应蛋白指导对死亡率无差异。
  • 两种策略均未显著增加复发(证据确定性极低至低)。

证据类型、等级与局限

  • 证据类型:系统评价与网络Meta分析,纳入随机对照试验,采用GRADE方法评估证据确定性。
  • 证据确定性:低至中等(降钙素原指导及C反应蛋白指导缩短抗菌疗程);极低至低(复发)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在重症成人脓毒症中,降钙素原或C反应蛋白指导的抗菌药物停用策略可能有益且安全。
  • 作者认为,在Sepsis-3、抗菌药物使用超过7天时,降钙素原指导有用。
  • 作者指出需要精心设计的研究聚焦监测方案和复发。

指南或共识出处

  • 原文引用的指南:近期指南推荐使用降钙素原指导抗生素停用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: In sepsis treatment, antibiotics are crucial, but overuse risks development of antibiotic resistance. Recent guidelines recommended the use of procalcitonin to guide antibiotic cessation, but solid evidence is insufficient. Recently, concerns were raised that this strategy would increase recurrence. Additionally, optimal protocol or difference from the commonly used C-reactive protein (CRP) are uncertain. We aimed to compare the effectiveness and safety of procalcitonin- or CRP-guided antibiotic cessation strategies with standard of care in sepsis.

DATA SOURCES: A systematic search of PubMed, Embase, CENTRAL, Igaku Chuo Zasshi, ClinicalTrials.gov , and World Health Organization International Clinical Trials Platform.

STUDY SELECTION: Randomized controlled trials involving adults with sepsis in intensive care.

DATA EXTRACTION: A systematic review with network meta-analyses was performed. The Grading of Recommendations, Assessments, Developments, and Evaluation method was used to assess certainty.

DATA SYNTHESIS: Eighteen studies involving 5023 participants were included. Procalcitonin-guided and CRP-guided strategies shortened antibiotic treatment (-1.89 days [95% CI, -2.30 to -1.47], -2.56 days [95% CI, -4.21 to -0.91]) with low- to moderate-certainty evidence. In procalcitonin-guided strategies, this benefit was consistent even in subsets with shorter baseline antimicrobial duration (7-10 d) or in Sepsis-3, and more pronounced in procalcitonin cutoff of "0.5 μg/L and 80% reduction." No benefit was observed when monitoring frequency was less than half of the initial 10 days. Procalcitonin-guided strategies lowered mortality (-27 per 1000 participants [95% CI, -45 to -7]) and this was pronounced in Sepsis-3, but CRP-guided strategies led to no difference in mortality. Recurrence did not increase significantly with either strategy (very low to low certainty).

CONCLUSIONS: In sepsis, procalcitonin- or CRP-guided antibiotic discontinuation strategies may be beneficial and safe. In particular, the usefulness of procalcitonin guidance for current Sepsis-3, where antimicrobials are used for more than 7 days, was supported. Well-designed studies are needed focusing on monitoring protocol and recurrence.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Kubo K, Sakuraya M, Sugimoto H, et al. Benefits and Harms of Procalcitonin- or C-Reactive Protein-Guided Antimicrobial Discontinuation in Critically Ill Adults With Sepsis: A Systematic Review and Network Meta-Analysis. Crit Care Med. 2024. PMID: 38949476. doi:10.1097/CCM.0000000000006366

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。